Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Change in Account Payables (2017 - 2025)

Cue Biopharma (CUE) has disclosed Change in Account Payables for 9 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 143.86% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 265.93% year-over-year, with the annual reading at $1.1 million for FY2025, 265.93% up from the prior year.
  • Change in Account Payables hit $1.6 million in Q4 2025 for Cue Biopharma, up from -$1.3 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.6 million in Q3 2024 to a low of -$3.6 million in Q4 2024.
  • Historically, Change in Account Payables has averaged $91019.9 across 5 years, with a median of $163500.0 in 2021.
  • Biggest five-year swings in Change in Account Payables: tumbled 2330.77% in 2023 and later skyrocketed 1970.16% in 2024.
  • Year by year, Change in Account Payables stood at $120398.0 in 2021, then skyrocketed by 422.43% to $629000.0 in 2022, then skyrocketed by 62.32% to $1.0 million in 2023, then plummeted by 457.49% to -$3.6 million in 2024, then skyrocketed by 143.86% to $1.6 million in 2025.
  • Business Quant data shows Change in Account Payables for CUE at $1.6 million in Q4 2025, -$1.3 million in Q3 2025, and -$157000.0 in Q2 2025.